Literature DB >> 11835348

Castleman's disease and lymphoma: report of eight cases in HIV-negative patients and literature review.

Claire Larroche1, Patrice Cacoub, Jean Soulier, Eric Oksenhendler, Jean-Pierre Clauvel, Jean-Charles Piette, Martine Raphael.   

Abstract

Castleman's disease (CD) is a rare atypical lymphoproliferative disorder associated with a risk of developing malignant lymphoma. We have recorded 8 HIV-negative patients presenting this association, 6 with non-Hodgkin's lymphoma (NHL) and 2 with Hodgkin's disease (HD). After literature review, we analyzed all reported cases of association CD-NHL (n = 23) and CD-HD (n = 27). NHL is more often associated with multicentric CD, its diagnosis being concurrent with CD diagnosis or occurring within 2 years. B-NHL is predominant (71%), and mantle cell lymphoma represents 40% of these B-NHL cases. NHL displays an aggressive course and is liable for death, especially in multicentric CD. HD occurs in localized CD of plasma cell type, usually in the same areas, is more often of interfollicular subtype, and its clinical course seems better than NHL. The association of CD and lymphoma seems to be more than coincidental, and its pathogenesis is discussed. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 11835348     DOI: 10.1002/ajh.10022

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  34 in total

1.  Interleukin-6-producing dermoid cyst associated with multicentric Castleman's disease.

Authors:  Shigeyuki Ebara; Soken-Nakazawa J Song; Hiroyuki Mizuta; Yasushi Ito; Kenji Hasegawa; Tsuneko Kamata; Teppei Matsumura-Nishikawa; Takafumi Ogawa; Jyunichi Soneda; Kazuyuki Yoshizaki
Journal:  Int J Hematol       Date:  2011-12-14       Impact factor: 2.490

Review 2.  NF-κB as a target for oncogenic viruses.

Authors:  Shao-Cong Sun; Ethel Cesarman
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

3.  Orbital pseudotumor as an initial manifestation of multicentric Castleman's disease.

Authors:  Masaru Inatani; Satoshi Kashii; Kazumasa Nosaka; Nobuyoshi Arima
Journal:  Jpn J Ophthalmol       Date:  2005 Nov-Dec       Impact factor: 2.447

Review 4.  Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients.

Authors:  Ethel Cesarman
Journal:  Cancer Lett       Date:  2011-04-13       Impact factor: 8.679

5.  Histomorphologic Spectrum in Hyaline Vascular Variant of Castleman Disease.

Authors:  Chaithra Gowthuvalli Venkataramana; Hema Kini; Debarshi Saha; Sharada Rai; Deepa Sowkur Anandarama Adiga; Ranjitha Rao; Cheryl Sarah Philipose
Journal:  J Clin Diagn Res       Date:  2017-08-01

6.  Diagnostic issues in a case of hodgkin lymphoma with castleman like features.

Authors:  Suganya K Reddy; Jinkala Sree Rekha; Sajini Elizabeth Jacob; Debdatta Basu
Journal:  Indian J Hematol Blood Transfus       Date:  2014-07-04       Impact factor: 0.900

Review 7.  Biologic Agents in the Treatment of Multicentric Castleman Disease.

Authors:  Konstantinos Kapriniotis; Savvas Lampridis; Sofoklis Mitsos; Davide Patrini; David R Lawrence; Nikolaos Panagiotopoulos
Journal:  Turk Thorac J       Date:  2018-10-01

8.  Three patients with both Hodgkin's lymphoma and Castleman's disease: Clinicopathologic correlations and lack of association with HHV-8.

Authors:  Saadiya Haque; Robert van Kirk
Journal:  Indian J Med Paediatr Oncol       Date:  2009-04

9.  IL-6-positive classical Hodgkin's lymphoma co-occurring with plasma cell type of Castleman's disease: report of a case.

Authors:  Akihito Momoi; Masaru Kojima; Takeshi Sakai; Junya Ajiro; Noriatsu Isahai; Kouichi Nagai; Sadao Aoki
Journal:  Int J Hematol       Date:  2013-01-29       Impact factor: 2.490

10.  Retroperitoneal Castleman's disease with colon cancer. A rare association.

Authors:  César Gómez-Raposo; Manuel Nistal; Javier De Castro Carpeño; Grevelyn Sosa Rotundo; Cristóbal Belda-Iniesta; Enrique Casado; Manuel González Barón
Journal:  Clin Transl Oncol       Date:  2008-04       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.